Physiology and pathology of endothelin-1 in renal mesangium

American Journal of Physiology - Renal Physiology

Volumn 285, Issue 4 54-4, 2003, Pages

  Sorokin, Andrey ^a   Kohan, Donald E ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Cell signaling; Mesangial cell; Pathophysiology; Receptor

Indexed keywords

ANGIOTENSIN; ARACHIDONIC ACID; ENDOTHELIN 1; NITRIC OXIDE;

CELL SECRETION; COMPLEX FORMATION; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; GLOMERULOPATHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY INTERSTITIUM; MESANGIUM; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0141813519     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00019.2003     Document Type: Review

References (122)

1. Aitsebaomo J, Kingsley-Kallesen M, Wu Y, Quertermous T, and Patterson C. Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter. J Biol Chem 276: 39197-39205, 2001.
2. 2-terminal kinase in mesangial cells. Kidney Int 51: 631-639, 1997.
3. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, and Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 83: 336-342, 1989.
4. Bakris GL, Bhandaru S, Akerstrom V, and Re RN. ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin. Am J Hypertens 7: 583-590, 1994.
5. Bakris GL and Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol Renal Fluid Electrolyte Physiol 264: F937-F942, 1993.
6. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, and McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121: 1860-1868, 2002.
7. Beck KF, Mohaupt MG, and Sterzel RB. Endothelin-1 inhibits cytokine-stimulated transcription of inducible nitric oxide synthase in glomerular mesangial cells. Kidney Int 48: 1893-1899, 1995.
8. Boffa JJ, Tharaux PL, Dussaule JC, and Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490-496, 2001.
9. Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N, and Endlich K. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 14: 37-45, 2003.
10. Cazaubon S, Chaverot N, Romero I, Girault J, Adamson P, Strosberg A, and Couraud P. Growth factor activity of endothelin-1 in primary astrocytes mediated by adhesion-dependent and -independent pathways. J Neurosci 17: 6203-6212, 1997.
11. Chen HC, Guh JY, Chang JM, and Lai YH. Differential effects of FMLP-activated neutrophils from patients with IgA nephropathy enhanced endothelin 1 production of glomerular mesangial cells. Nephron 89: 274-279, 2001.
12. Chen J, Gu Y, Lin F, Yang H, Zhu W, Ma J, and Lin S. Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chin Med J (Engl) 115: 972-978, 2002.
13. Chen S, Evans T, Deng D, Cukiernik M, and Chakrabarti S. Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron 90: 86-94, 2002.
14. Chen Y, Sun Y, Lin J, Zhou A, and Wang H. Research on the mechanism of endothelin inflammatory effects on human mesangial cells. Chin Med J (Engl) 110: 530-534, 1997.
15. Coroneos EJ, Kester M, Maclouf J, Thomas P, and Dunn MJ. Calcium-regulated protein tyrosine phosphorylation is required for endothelin-1 to induce prostaglandin endoperoxide synthase-2 mRNA expression and protein synthesis in mesangial cells. J Am Soc Nephrol 8: 1080-1090, 1997.
16. Derylo B, Babazono T, Glogowski E, Kapor-Drezgic J, Hohman T, and Whiteside C. High glucose-induced mesangial cell altered contractility: role of the polyol pathway. Diabetologia 41: 507-515, 1998.
17. Dhein S, Hochreuther S, Aus Dem Spring C, Bollig K, Hufnagel C, and Raschack M. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 293: 351-359, 2000.
18. Duan SB, Liu FY, Luo JA, and Peng YM. Assessment of urinary endothelin-1 and nitric oxide levels and their relationship with clinical and pathologic types in primary glomerulo-nephritis. Yonsei Med J 40: 425-429, 1999.
19. Dulin N, Sorokin A, Reed E, Elliott S, Kehrl J, and Dunn M. RGS3 inhibits G protein-mediated signaling via translocation to the membrane and binding to Gα. Mol Cell Biol 19: 714-723, 1999.
20. Ebihara I, Nakamura T, Tomino Y, and Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 12: 1001-1006, 1997.
21. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, and Luscher T. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ ROCK and mitogen-activated protein kinase. Circ Res 89: 583-590, 2001.
22. Feldman DL, Mogelesky TC, Chou M, and Jeng AY. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol 36: S342-S345, 2000.
23. Foschi M, Chari S, Dunn M, and Sorokin A. Biphasic activation of p21ras by endothelin-1 sequentially activates the ERK cascade and phosphatidylinositol 3-kinase. EMBO J 16: 6439-6451, 1997.
24. Foschi M, Franchi F, Han J, La Villa G, and Sorokin A. Endothelin-1 induces serine phosphorylation of the adaptor protein p66Shc and its association with 14-3-3 protein in glomerular mesangial cells. J Biol Chem 276: 26640-26647, 2001.
25. Foschi M, Sorokin A, Pratt P, McGinty A, La Villa G, Franchi F, and Dunn M. Preproendothelin-1 expression in human mesangial cells: evidence for a p38 mitogen-activated protein kinase/protein kinases-C-dependent mechanism. J Am Soc Nephrol 12: 1137-1150, 2001.
26. 2 production by endothelin 1 in cultured rat mesangial cells. Exp Nephrol 4: 340-349, 1996.
27. Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I, and Egido J. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50:962-972, 1996.
28. Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, Lopez-Armada MJ, Plaza JJ, Gonzalez E, and Egido J. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27: 885-892, 1996.
29. Goodall T, Kind CN, and Hammond TG. FK506-induced endothelin release by cultured rat mesangial cells. J Card Pharm 26, Suppl 3: S482-S485, 1995.
30. Goruppi S, Bonventre J, and Kyriakis J. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 216: 5427-5436, 2002.
31. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, and Wong NC. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58: 1534-1545, 2000.
32. Herman WH, Emancipator SN, Rhoten RL, and Simonson MS. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol Renal Physiol 275: F8-F17, 1998.
33. Hirahashi J, Nakaki T, Hishikawa K, Marumo T, Yasumori T, Hayashi M, Suzuki H, and Saruta T. Endothelin-1 inhibits induction of nitric oxide synthase and GTP cyclohydrolase I in rat mesangial cells. Pharmacology 53: 241-249, 1996.
34. Hiraoka J, Arai H, Yoshimasa T, Takaya K, Miyamoto Y, Yamashita J, Suga S, Ogawa Y, Shirakami G, Itoh H, Yamori Y, and Nakao K. Augmented expression of the endothelin-A receptor gene in cultured mesangial cells from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22: S191-S192, 1995.
35. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, Bauer C, Neumayer HH, and Raschack M. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87: 161-169, 2001.
36. 1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes 50: 2376-2383, 2001.
37. Hua H, Munk S, and Whiteside CI. Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am J Physiol Renal Physiol 284: F303-F312, 2003.
38. Hughes AK, Padilla E, Kutchera WA, Michael JR, and Kohan DE. Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells. Kidney Int 47: 53-61, 1995.
39. Hughes AK, Stricklett PK, Padilla E, and Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 49: 181-189, 1996.
40. Humbert M and Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxf) 42: 191-193, 2003.
41. Ikeda M, Kohno M, Horio T, Yasunari K, Yokokawa K, Kano H, Minami M, Hanehira T, Fukui T, and Takeda T. Effect of thrombin and PDGF on endothelin production in cultured mesangial cells derived from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22: S197-S198, 1995.
42. Ikeda M, Kohno M, and Takeda T. Endothelin production in cultured mesangial cells of spontaneously hypertensive rats. Hypertension 25: 1196-1201, 1995.
43. Imamura T, Huang J, Dalle S, Ugi S, Usui I, Luttrell L, Miller W, Lefkowitz R, and Olefsky J. β-Arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport. J Biol Chem 276: 43663-43667, 2001.
44. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, and Masaki T. The human preproendothelin-1 gene. J Biol Chem 264: 14954-14959, 1989.
45. Inui D, Yoshizumi M, Suzaki Y, Kirima K, Tsuchiya K, Houchi H, Kagami S, and Tamaki T. Effect of endothelin-1(1-31) on p38 mitogen-activated protein kinase in cultured human mesangial cells. Life Sci 68: 635-645, 2000.
46. Ishaque A, Dunn M, and Sorokin A. Cyclooxygenase-2 inhibits TNFa-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem 278: 10629-10640, 2003.
47. Iwamoto T, Tamaki K, Nakayama M, Okuda S, and Fujishima M. Effect of endothelin 1 on fibrinolysis and plasminogen activator inhibitor 1 synthesis in rat mesangial cells. Nephron 73: 273-279, 1996.
48. Iwasaki S, Homma T, Matsuda Y, and Kon V. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 270: 6997-7003, 1995.
49. Jaffer FE, Knauss TC, Poptic E, and Abboud HE. Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int 38: 1193-1198, 1990.
50. Jeng AY, Mulder P, Kwan AL, and Battistini B. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 80: 440-449, 2002.
51. Kalra PR, Moon JC, and Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195-197, 2002.
52. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, and Cotter G. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41: 204-210, 2003.
53. Karam H, Bruneval P, Clozel JP, Löffler BM, Bariéty J, and Clozel M. Role of endothelin in acute renal failure due to rhabdomyloysis in rats. J Pharm Exp Ther 274: 481-486, 1995.
54. Kedzierski R and Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876, 2001.
55. Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, and Kuroda Y. Endothelin-1 is a potent stimulator of alpha1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun 299: 555-561, 2002.
56. 13. Am J Physiol Cell Physiol 276: C930-C937, 1999.
57. Kohan D. Endothelins in the normal and diseased kidney. Am J Kid Dis 29: 2-26, 1997.
58. Kohan DE. Production of endothelin-1 by rat mesangial cells: regulation by tumor necrosis factor. J Lab Clin Med 119: 477-484, 1992.
59. Kohno M, Horio T, Ikeda M, Yokokawa K, Fukui T, Yasunari K, Kurihara N, and Takeda T. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 42: 860-866, 1992.
60. Kohno M, Horio T, Yokokawa K, Kurihara N, and Takeda T. C-type natriuretic peptide inhibits thrombin-and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′-monophosphate. Hypertension 19: 320-325, 1992.
61. Kohno M, Yokokawa K, Horio T, Ikeda M, Kurihara N, Mandal AK, and Takeda T. Heparin inhibits endothelin-1 production in cultured rat mesangial cells. Kidney Int 45: 137-142, 1994.
62. Kohno M, Yokokawa K, Mandal AK, Horio T, Yasunari K, and Takeda T. Cardiac natriuretic peptides inhibit cyclosporine-induced production of endothelin in cultured rat mesangial cells. Metabolism 44: 404-409, 1995.
63. Krum H, Viskoper RJ, Lacourciere Y, Budde M, and Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338:784-790, 1998.
64. Largo R, Gomez-Garre D, Liu XH, Alonso J, Blanco J, Plaza JJ, and Egido J. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension 29: 1178-1185, 1997.
65. Lepailleur-Enouf D, Valdenaire O, Philippe M, Jandrot-Perrus M, and Michel J. Thrombin induces endothelin expression in arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 278: H1606-H1612, 2000.
66. 2+-induced regulation of ion channel and MAP kinase functions. Nature 376: 737-745, 1995.
67. Li M, Chen Y, Zhang Z, and Gao J. Inhibition of mesangial cell proliferation by antisense oligodeoxynucleotide targeting preproendothelin-1 mRNA in vitro. Chin Med J (Engl) 112: 790-793, 1999.
68. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, and Clark A. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 3: 381-387, 2001.
69. Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hurlimann D, Philipp S, Notter T, Noll G, and Ruschitzka F. Hemodynamic and neurohumoral effects of selective endothelin A [ET(A)] receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106:2666-2672, 2002.
70. 2+ handling of human small arteries. Am J Physiol Heart Circ Physiol 279: H1228-H1238, 2000.
71. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi P, Lanfrancone L, and Pelicci P. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402: 309-313, 1999.
72. Morimoto T, Hasegawa K, Wada H, Kakita T, Kaburagi S, Yanazume T, and Sasayama S. Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. J Biol Chem 276: 34983-34989, 2001.
73. Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, and Barrish JC. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[(2′ -[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1, 1′-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ETA selective antagonist. J Med Chem 46: 125-137, 2003.
74. Mylona P and Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio net Editorial Team. Eur J Heart Fail 1: 197-200, 1999.
75. Nakamura T, Ebihara I, Fukui M, Tomino Y, and Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899, 1995.
76. Nakov R, Pfarr E, and Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 15: 583-589, 2002.
77. Nambi P, Gellai M, Wu HL, and Prabhakar U. Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1? Biochem Biophys Res Commun 241: 212-214, 1997.
78. Nord EP. Role of endothelin in acute renal failure. Blood Purif 15: 273-285, 1997.
79. Nutt LK and O'Neil RG. Effect of elevated glucose on endothelin-induced store-operated and non-store-operated calcium influx in renal mesangial cells. J Am Soc Nephrol 11: 1225-1235, 2000.
80. Orth SR, Amann K, Gehlen F, Unger L, Wagner J, Raschack M, and Ritz E. Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol 36: S232-S237, 2000.
81. Owada A, Tomita K, Terada Y, Sakamoto H, Nonguchi H, and Marumo F. Endothelin (ET)-3 stimulates cyclic guanosine 3′,5′-monophosphate production via ETB receptor by producing nitric oxide in isolated rat glomerulus, and in cultured rat mesangial cells. J Clin Invest 93: 556-563, 1994.
82. Parameswaran N, Hall CS, Boeck BC, Sparks HV, Gallo KA, and Spielman WS. Mixed lineage kinase 3 inhibits platelet-derived growth factor-stimulated DNA synthesis and matrix mRNA expression in mesangial cells. Cell Physiol Biochem 12: 325-334, 2002.
83. Pearson G, Robinson F, Beers G, Xu B, Karandikar M, Berman K, and Cobb M. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
84. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, and Pelicci P. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104, 1992.
85. Remuzzi G, Perico N, and Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev 1: 986-1001, 2002.
86. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903, 2002.
87. Ruiz-Ortega M, Gomez-Garre D, Liu XH, Blanco J, Largo R, and Egido J. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J Am Soc Nephrol 8: 756-768, 1997.
88. Sakamoto H, Sasaki S, Nakamura Y, Fushimi K, and Marumo F. Regulation of endothelin-1 production in cultured rat mesangial cells. Kidney Int 41: 350-355, 1992.
89. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, and Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 93: 992-997, 2000.
90. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Morita H, Kumada M, Yazaki Y, Nagai R, and Kimura K. Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med 80: 105-116, 2002.
91. Simonson M and Dunn MJ. Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates β-adrenergic-mediated cyclic adenosine monophosphate accumulation. J Clin Invest 85: 790-797, 1990.
92. Simonson M, Jones J, and Dunn M. Cytosolic and nuclear signaling by endothelin peptides: mesangial response to glomerular injury. Kidney Int 41: 542-545, 1992.
93. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 73: 375-411, 1993.
94. Simonson MS and Dunn MJ. Ca2+ signaling by distinct endothelin peptides in glomerular mesangial cells. Exp Cell Res 192: 148-156, 1991.
95. Simonson MS and Dunn MJ. Cellular signaling by peptides of the endothelin gene family. FASEB J 4: 2989-3000, 1990.
96. Simonson MS and Rooney A. Characterization of endothelin receptors in mesangial cells: evidence for two functionally distinct endothelin binding sites. Mol Pharmacol 46: 41-50, 1994.
97. Simonson MS, Wann S, Mene P, Dubyak GR, Kester M, and Dunn MJ. Endothelin-1 activates the phosphoinositide cascade in cultured glomerular mesangial cells. J Cardiovasc Pharmacol 13: S80-S84, 1989.
98. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 83: 708-712, 1989.
99. Sorokin A, Kozlowski P, Graves L, and Philip A. Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. J Biol Chem 276: 21521-21528, 2001.
100. Sugimoto K, Tsuruoka S, and Fujimura A. Renal protective effect of YM598, a selective endothelin ETA receptor antagonist, against diabetic nephropathy in OLETF rats. Eur J Pharmacol 450:183-189, 2002.
101. Sugimoto T, Haneda M, Sawano H, Isshiki K, Maeda S, Koya D, Inoki K, Yasuda H, Kashiwagi A, and Kikkawa R. Endothelin-1 induces cyclooxygenase-2 expression via nuclear factor of activated T-cell transcription factor in glomerular mesangial cells. J Am Soc Nephrol 12: 1359-1368, 2001.
102. Takeda M, Breyer MD, Noland TD, Homma T, Hoover RL, Inagami T, and Kon V. Endothelin-1 receptor antagonist: effects on endothelin- and cyclosporine-treated mesangial cells. Kidney Int 42: 1713-1719, 1992.
103. Takeda M, Iwasaki S, Hellings SE, Yoshida H, Homma T, and Kon V. Divergent expression of EtA and EtB receptors in response to cyclosporine in mesangial cells. Am J Pathol 144: 473-479, 1994.
104. Tan MS, Lee YJ, Shin SJ, and Tsai JH. Oxidized low-density lipoprotein stimulates endothelin-1 release and mRNA expression from rat mesangial cells. J Lab Clin Med 129: 224-230, 1997.
105. Terada Y, Inoshita S, Nakashima O, Yamada T, Tamamori M, Ito H, Sasaki S, and Marumo F. Cyclin D1, p16, and retinoblastoma gene regulate mitogenic signaling of endothelin in rat mesangial cells. Kidney Int 53: 76-83, 1998.
106. Tian W, Zhang Z, and Cohen D. MAPK signaling and the kidney. Am J Physiol Renal Physiol 279: F593-F604, 2000.
107. Tojo A, Fujita T, and Wilcox CS. Omapatrilat: still a promise in salt-sensitive hypertension? J Hypertens 21: 31-32, 2003.
108. Tolloczko B, Tao F, Zacour M, and Martin J. Tyrosine kinase-dependent calcium signaling in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 278: L1138-L1145, 2000.
109. Tsiani E, Lekas P, Fantus IG, Dlugosz J, and Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 282: E161-E169, 2002.
110. Vemulapalli S, Chintala M, Stamford A, Watkins R, Chiu P, Sybertz E, and Fawzi A. Renal effects of SCH 54470: a triple inhibitor of ECE, ACE, and NEP. Cardiovasc Drug Rev 15:260-272, 1997.
111. 2+/calmodulin-dependent protein kinase II stimulates c-fos transcription and DNA synthesis by a Src-based mechanism in glomerular mesangial cells. J Am Soc Nephrol 14: 28-36, 2003.
112. Wang Y, Simonson MS, Pouyssegur J, and Dunn MJ. Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. Biochem J 287: 589-594, 1992.
113. Watts S. 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension 35: 244-248, 2000.
114. Whiteside C and Dlugosz J. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 282: F975-F980, 2002.
115. Yamashita K, Discher D, Hu J, Bishopric N, and Webster K. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276: 12645-12653, 2001.
116. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
117. Yao J, Morioka T, Li B, and Oite T. Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells. Am J Physiol Renal Physiol 280: F628-F635, 2001.
118. 2+ signaling in cultured rat mesangial cells. Life Sci 53: 1631-1641, 1993.
119. Yoshimura A, Iwasaki S, Inui K, Ideura S, Koshikawa S, Yanagisawa M, and Masaki T. Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int 48: 1290-1297, 1995.
120. 2, endothelin-1 and endothelin-3 in rat nephrotoxic serum nephritis. Tohoku J Exp Med 178: 357-369, 1996.
121. 2 analogue. Lab Invest 64: 16-20, 1991.
122. Zubkov A, Rollins K, Parent A, Zhang J, and Bryan R Jr. Mechanism of endothelin-1-induced contraction in rabbit basilar artery. Stroke 31: 526-533, 2000.